pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1284 |
Genomic Coordinates | chr3: 71541970 - 71542089 |
Synonyms | MIRN1284, hsa-mir-1284, MIR1284 |
Description | Homo sapiens miR-1284 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1284 | ||||||||||||||||||||||||||||||||||||
Sequence | 30| UCUAUACAGACCCUGGCUUUUC |51 | ||||||||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||||||||
Experiments | Illumina | DRVs in miRNA |
|
||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | TTC33 | ||||||||||||||||||||
Synonyms | OSRF | ||||||||||||||||||||
Description | tetratricopeptide repeat domain 33 | ||||||||||||||||||||
Transcript | NM_012382 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on TTC33 | |||||||||||||||||||||
3'UTR of TTC33 (miRNA target sites are highlighted) |
>TTC33|NM_012382|3'UTR 1 AGCAGTATGCATAGGATTATTTGAATCTGTCTTTTTGATTGCCTCTTGAAGTTTTGACATAGAGACATTTACTCTGGAGA 81 TAGATAGGAGAACGCCTGGTTGTAAAATATGTTTTTCAGATGAGGCATATAAAAACTAAAATGGCAGGATTATTGTATAG 161 TGTTTGGAATATGCTTTGATAAGTTATGATTTATATTTCTCAAGGTTAAAATTCTGAGTAAAATGGTCTTTGATTAATAA 241 ACTTAGTTTAATCTGAATATGTAAATGAATACATTTTAAAGACAAAACTTGAAAAATGTATTCTTGAATAGTGAATAATT 321 TGATCAATGTTACTGAAATGCTGTCTCAACTTTTGTTTTATGATAAAGGAAGTGTGTGATTTCCCTCCCTCTGAGAAATA 401 TACTGCGCTTAATATTTGCTGTCTTTTTCTTGCTTCATTAGAGTAAGTCTGTCAGAAAGCTTGAATATTTTTGACATTCA 481 TTTTGATTCAAAGTTGTCATTTGGTTATATGTGGAATCTTTGAAAGTTTGGCTGAAAATGCACACAAATGTGTACATTCT 561 GAACATTTTCTGAAGTTTCTCTTAATTCTGATTTGTGTTTCTGTTTTGACTTTGAAGTTGTAACAATGATAGTTGTCTCC 641 TTCAGTATTTGGTAAAAGTGTAAAGTATTGATAAATATGAGAATGATGGTTTTATTTTTTAATTGTTACAGTAAGTAATC 721 CTTACCACAAATGAGTCATTTTTAAAATATGCATTTTTAAATGAATGGCTTTTACAGATAGGTTAATGACAATTGTACTG 801 CTATATTATCCCAGTCAAAACCAATACTTTCTTTTCTTTATTTTACAAAGCTTTAAAAACCCTGGAAACAACTTACTTCT 881 TGCTTGTGTCTTTCCATTTGATGACTGGGAATTACTTTTCTAGATAACTTTTTTTGAAACTACTCAGTGAAATGAAAAAT 961 AATTACAATTTTAAATAGCTAATTATATCTTTCTAAAAATAAAAAAGTAGGGCTGTTATTAGAGTGCCAATGAATAAATA 1041 ACTTAAGCACAAAATACATAGAAATTGGAATGTGATTTATAGTACAATCTCATGAGTATGAAAAGGCTATATTAAAAAAA 1121 ATTTTATTGAAAGTCCACAGTCATATTCACAAACCAATACTGTCATTGCTAATCTGAACTATTATTTTTATACTATATAT 1201 TGTAGTACAATAATATAGAACTGTTGGGTTCTGTTACTTCTGACACTCAGGAAGATACTATTGGTGTATTAATTTTATCT 1281 TTGTTAGAGATGAAAGTAGCCCACTTTATGTTAAAGATCTTACTACTGTTGGAGCTTATAAGTAATGATCTACATTTTTT 1361 ATGAAGATGGTTTTTAAAACTTTTGTTTTATTGGAATGCATATCTCTTTTCAGGGTTGGAGAAATTAGCACTTGCCTTGA 1441 AAAGAATATTCTTTCCTTAAGTTATATCATCAGAAAATTAGCTCTGGTTAGAGAGGTTAGTTTCAGAGTGCTCCAAAAAA 1521 TATGTTAATTATTTTATTTTGTTTAATAAAGAACATTCTCAAAACGTAAATAGGTATCTAGAGAAGTGAGTACTCAACAT 1601 TTGGTATATTGTTTTGAGTAATGGATGTTTGTTTTTTGTGTAATTTGTGAATAAATAGTTTTTTTCTGCATTTTGAAGAT 1681 TTTCCTATTATTTTATGTTGTTAGCTTTTGAAAAATTAGATTGATCTACTTAGTGTCTTTCTTATATGAACTTAATATAT 1761 TTAAAGTACCTTGCATGGTGCCTCACACATGAAGTAATGCCAGCTATTTCAGTAAATGCTAGCTATTTCTATGAAGAACT 1841 TGAGTTAGTTTGGAGATATTTAACCTCAATTTCCTCTGATTTTAAAAAAGGAGAACTTTTTTTGTAATCCTTTCCTTATC 1921 TGAAAGTAAGAAGTCTCTGATTCCAGTATTATAGGAGAGATAGTGGGATTTTTCTTGACAGGGTCTATAGCTCAAGTCCC 2001 AAAGAGGCAAGACTCAGGATGGAATGCATGTGGCCACTAGGCCCTGTTATAAGAACCTAGTGTTTCCTCTGTACTGGCAT 2081 GGTAGGCCAAGTTAGTCTCTTTCTTACCCAGATATAAGACATAAAATAGTTTAGACATAAGACAGAGGAGAAAAAGAAAC 2161 AGTAAGTTATGGAGAAGGAAGGCAGCTCATTTCTGCAGGCCCCTCAAAATGCTTATTTTAGCTCATACTCTTCTATGCGT 2241 GAAGAGAAAAATGCACCCATTATTTTACAAGGATGTGAATACTGATATACAAACATAGACTAAGCTTGTTAATTTTAATA 2321 ACAAATCTTTATGAATCTGAAGAGAATTGATGTTCATGATAATGATATAGATGTTTAATATACTTTCTGAAATAACACTG 2401 TTTACTGTTCAAGTTATATTGACTATAATTTACATTATTCTTGTTTGAGAATTGTATGGCATAGACACTCATTAGTCAGA 2481 GTGTCTAGACATCCAGACCATGCCTGATAACACAAGAATCATATATCATTCTCTAGAAAACAGGCTGTTTGGTTATAGAG 2561 TATTTATCTTAAATATATTAACAGACACTACATAAACATTGAAAAGCCATGCAAGTTATAGCTCACAGGAGCCAGATCTA 2641 CTGCAACTGGGGCCTACATACAAAATTTTATGGCAGTGGTTTCAGTATGACAATCTTTTGAATTGATGCCGTATGGTAAA 2721 ACTATAAAGATTTTTTAAAAGCTCTGTCTCAGCTAGAATTTTTAAGATTATAACTGAACAGTATAGCCCTTTTAGTTGTT 2801 TGAAAATTACATAATGATTCAAAAGCTTGTTTCACTGCCTTTCCCAGCACTAAGAAAATTAACAATCATTTCTTTTAATT 2881 TCCTTGAATCAGAGCCATTCTAAAGTGACTCTGGACCAGCAATTCTGAGCTATGATTTCATGATACATGTATTAATATCT 2961 AAATGAGTTGTGAGTTGACATAAGAACCATAGTTCCATAATAATTATCTTCAAATCAATGGATATCTTAAATGTGTTTTT 3041 TTCTTCCTTAGAGATTATTATTAAACTGATGTATTTGATAATAAAGAATTTTAGGACTGAGAAAGTTAAGTTTTTCTTAC 3121 CAATAATAAGATATTGAAATATATAAATTATAAAACAGAAATAAAATGAAATAAAGGAGGTTATCCCTAAAGTCATTTAC 3201 CTTAGTCACTTGCAATTAAATATGGTTACTTCGGAAGAAGAAGTGTGGCCCTAAAGCTACTGTAACATGAATCATGCCCT 3281 AATGTGCACTATATATGAACTACTTTGGTCAGAAGGCAGCGGCGGGTAAGGATGGCTTCCTCTCACAGTGCTTCTTAGGC 3361 TATCCATTTACCAAGGAATTCTAATCTCTTTCTCTCACTTCACCAGGAAAGGAGGGAGTTTAAGATATAGAACTGGGCAT 3441 GCTAGCCTCTTTTTTCCCTTTTGTGGATTTGTCATAACTGCAGAGAACCGATGTTGTGGTCTCTTGCCAGCTACATTGTG 3521 AACCTTGCAGTGAAAGTTCTTTGCCTCTGCAAAGGGAGATTTGTGCTTGTGCAGAACTGCCCATGCCTTAGTAAGCAGGT 3601 CTGTCTAATTCTAAGTTCAATATCTGGTGGCTATTGTTGGCATAAACTTAAAGTACATCCTCTAACCTAGCCTTTTTCAG 3681 CAGTAAACTTAAAATATTGAATCTCCATCTGTCTGTGTCTCAAGTGGTTCAGAGGTCAGGAGAGGAGAGGGACATTATTT 3761 TATGACTCCCTCAAACTTTAACAAAGACTAGTGCAGATTATATTTCGAAGTAAGCATGAGATATATTAAAAACCACATGT 3841 GGGAATTCTTTCCTAATTTTAGAGGTTTTTTTTAAATAATGGAAATTCTATTGAAATTGAGTAGTGTTAATTACAAGGCA 3921 ACAGGTAAACATTTGTTCAGGATATTTAAAAGGTCTGCTGAGTTGGAATTGTGACAGACCACATTGTTGACTCTAGATTG 4001 AATTGGAAGGGAAGAATGTGAAATGAATTAGGATATCCTCTGTTCACCTCTATTAACTTTCTTAAATGAGTATAACTTAG 4081 AAATAATAAAATGCAAGTATTTTAACGTTATAGTTGGGAGAGTTTTGACAAATGTAAACACCCACTTCACCACCACTACC 4161 ATCCTGATATAGTGTGTGTCCATCACCCAAAAAGTTCTCTAAAGCCCTTTTGCAGTTGGTTCCCCTCCACCTGAACAGCC 4241 ATCCCTAGTCAACTACTTTTCTGCTTTCTGTGGCTATACGTTAGATTTGACTTCAGAATTCTAGAGTTTGAAATAAATAG 4321 GCCATATAATATGCACTCTTTTTGTGTCTGACTTTTTTTTTGCTTAACATGATGCTTTTGAAACCCATCCATGTTGAGAT 4401 TCATCCATGTTATCATGTGTATCAATAATAAGTTCCTTTTTATTGCTGAATAGTATTCTAGTATATAGATATACCACAAT 4481 TTGTTTAGCTGTTCACCTATTGATGGACATTTAGGTTGTTTCAAGTTTTGATCTATTATGAATAAAGCTGCTATATATAT 4561 AAATCACAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545214. RNA binding protein: AGO3. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
CLIP-seq Support 1 for dataset GSM545214 | |
---|---|
Method / RBP | PAR-CLIP / AGO3 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000337702.4 | 3UTR | CAUAUAAAAACUAAAAUGGCAGGAUUAUU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
46 hsa-miR-1284 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT035831 | PRRC2B | proline rich coiled-coil 2B | 1 | 1 | ||||||||
MIRT079621 | DNAJB4 | DnaJ heat shock protein family (Hsp40) member B4 | 2 | 2 | ||||||||
MIRT149901 | LDLR | low density lipoprotein receptor | 2 | 2 | ||||||||
MIRT182786 | TOR1AIP2 | torsin 1A interacting protein 2 | 2 | 2 | ||||||||
MIRT188827 | TMTC3 | transmembrane and tetratricopeptide repeat containing 3 | 2 | 2 | ||||||||
MIRT198187 | EIF4A1 | eukaryotic translation initiation factor 4A1 | 3 | 1 | ||||||||
MIRT245472 | ARID5B | AT-rich interaction domain 5B | 2 | 2 | ||||||||
MIRT252245 | PMAIP1 | phorbol-12-myristate-13-acetate-induced protein 1 | 2 | 6 | ||||||||
MIRT269363 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 2 | ||||||||
MIRT320406 | HOXA9 | homeobox A9 | 2 | 4 | ||||||||
MIRT474722 | KIF13A | kinesin family member 13A | 2 | 6 | ||||||||
MIRT497926 | BTG1 | BTG anti-proliferation factor 1 | 2 | 2 | ||||||||
MIRT504264 | C1orf147 | chromosome 1 open reading frame 147 | 2 | 4 | ||||||||
MIRT520449 | TSPAN2 | tetraspanin 2 | 2 | 4 | ||||||||
MIRT524092 | DNAJB14 | DnaJ heat shock protein family (Hsp40) member B14 | 2 | 4 | ||||||||
MIRT528639 | SENP6 | SUMO1/sentrin specific peptidase 6 | 2 | 2 | ||||||||
MIRT537385 | FGF2 | fibroblast growth factor 2 | 2 | 2 | ||||||||
MIRT538902 | BRI3BP | BRI3 binding protein | 2 | 2 | ||||||||
MIRT542095 | KCNK10 | potassium two pore domain channel subfamily K member 10 | 2 | 6 | ||||||||
MIRT543976 | PRR23A | proline rich 23A | 2 | 2 | ||||||||
MIRT549625 | ADCYAP1 | adenylate cyclase activating polypeptide 1 | 2 | 4 | ||||||||
MIRT554298 | SIPA1L2 | signal induced proliferation associated 1 like 2 | 2 | 2 | ||||||||
MIRT554872 | RCAN2 | regulator of calcineurin 2 | 2 | 2 | ||||||||
MIRT567623 | FAM210A | family with sequence similarity 210 member A | 2 | 2 | ||||||||
MIRT571137 | TTC33 | tetratricopeptide repeat domain 33 | 2 | 2 | ||||||||
MIRT576361 | Pxdn | peroxidasin | 2 | 2 | ||||||||
MIRT611088 | PHF8 | PHD finger protein 8 | 2 | 2 | ||||||||
MIRT612380 | TCTE1 | t-complex-associated-testis-expressed 1 | 2 | 4 | ||||||||
MIRT613725 | MTPN | myotrophin | 2 | 2 | ||||||||
MIRT614627 | YAE1D1 | Yae1 domain containing 1 | 2 | 2 | ||||||||
MIRT615818 | KIAA1549L | KIAA1549 like | 2 | 2 | ||||||||
MIRT620949 | TBCK | TBC1 domain containing kinase | 2 | 2 | ||||||||
MIRT622339 | SCN4A | sodium voltage-gated channel alpha subunit 4 | 2 | 2 | ||||||||
MIRT623219 | MTA3 | metastasis associated 1 family member 3 | 2 | 4 | ||||||||
MIRT628932 | SLC1A4 | solute carrier family 1 member 4 | 2 | 2 | ||||||||
MIRT632121 | FKBP9 | FK506 binding protein 9 | 2 | 2 | ||||||||
MIRT635877 | COX17 | COX17, cytochrome c oxidase copper chaperone | 2 | 2 | ||||||||
MIRT636485 | IKBKG | inhibitor of nuclear factor kappa B kinase subunit gamma | 2 | 2 | ||||||||
MIRT653097 | SRSF7 | serine and arginine rich splicing factor 7 | 2 | 2 | ||||||||
MIRT655048 | PKN2 | protein kinase N2 | 2 | 2 | ||||||||
MIRT686946 | SFT2D3 | SFT2 domain containing 3 | 2 | 2 | ||||||||
MIRT692724 | INPP5B | inositol polyphosphate-5-phosphatase B | 2 | 2 | ||||||||
MIRT697282 | ZNF800 | zinc finger protein 800 | 2 | 2 | ||||||||
MIRT698995 | SPAG9 | sperm associated antigen 9 | 2 | 2 | ||||||||
MIRT704462 | CRNKL1 | crooked neck pre-mRNA splicing factor 1 | 2 | 2 | ||||||||
MIRT715163 | FIG4 | FIG4 phosphoinositide 5-phosphatase | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|